Concepts
Tesamorelin vs Ipamorelin: what actually differs
Updated
Both appear in growth-hormone-axis literature, but from opposite ends of the structure spectrum — one a length-modified analogue of a much longer sequence, the other a five-residue peptide built for selectivity.
Same research axis, different starting points
Tesamorelin and Ipamorelin both turn up in literature examining the hypothalamic–pituitary axis, which is enough to make them look interchangeable at a glance. They are not the same class of molecule, and the distinction is structural before it is anything else.
Structure and length
Tesamorelin is a synthetic analogue of a naturally occurring hypothalamic peptide, modified at its terminus specifically to resist enzymatic breakdown. The modification is the defining feature of the molecule — it is itself a subject of study, as an example of how analogues are engineered for resistance to degradation.
Ipamorelin is a five-amino-acid synthetic peptide — one of the shortest sequences that appears regularly in this literature. At that length, counterion and residual salt account for a proportionally larger share of a vial's weighed mass than they would in a longer peptide, which is why net peptide content is worth particular attention on its certificate.
What each is studied for
Tesamorelin's literature centers on axis-regulation research, examined in laboratory models, alongside its use as a characterized ligand in receptor-binding work and as a case study in peptide stability engineering.
Ipamorelin's defining property is different: it is studied for its selectivity, acting at one receptor with comparatively little activity elsewhere. That narrow selectivity is precisely what makes it useful as an experimental control in binding and competition studies — a role a broader-acting molecule cannot fill as cleanly.
Why they are supplied together rather than separately
We supply both within a pre-combined blend rather than as standalone vials. The rationale sits at the level of composition, not use: pairing a longer regulatory-axis analogue with a short, highly selective peptide gives researchers two components with complementary, well-characterized roles in the same area of study, prepared and documented together.
What a blend's certificate needs to show
A certificate for combined material should establish each component's identity, purity, and net peptide content separately — not report the combination as a single figure. A certificate that collapses two compounds into one number has told you less than it appears to, for the same reason discussed on the certificate-of-analysis page.
Common questions
- Are Tesamorelin and Ipamorelin the same class of peptide?
- No. Tesamorelin is a modified analogue of a much longer, naturally occurring sequence. Ipamorelin is a short, five-residue synthetic peptide. Both appear in the same area of literature, but they differ in length and structural class.
- Why is Ipamorelin studied specifically for receptor selectivity?
- Because it acts narrowly at one receptor with comparatively little activity elsewhere. That property is what makes it useful as an experimental control — a molecule with broader activity would confound a study designed to isolate one receptor's behavior.
- Does a blend's certificate report one purity figure for both compounds combined?
- It should not. Each component's identity, purity and net peptide content should be established separately on the certificate. A single combined figure obscures exactly the information a researcher would need to characterize either compound individually.
Check a certificate
Certificates are published per lot. The number printed on a vial retrieves the analysis of that specific batch.
Look up a lot number